利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

159 条记录 (耗时 0.028 秒)

    YEAST VECTORS AND PROCESS FOR PRODUCING PROTEINS WITH THE USE OF THE SAME
    113.
    发明公开
    YEAST VECTORS AND PROCESS FOR PRODUCING PROTEINS WITH THE USE OF THE SAME 失效
    HEFEVEKTOREN UND VERFAHRENFÜRIHRE BENUTZUNGFÜRDIE PRODUKTION VON PROTEINEN。

    公开(公告)号：EP0950712A1

    公开(公告)日：1999-10-20

    申请号：EP97935860.3

    申请日：1997-08-22

    申请人： KIRIN BEER KABUSHIKI KAISHA

    发明人： KONDO, Keiji, Kiban Gijutsu Kenkyusho ,  MIURA, Yutaka, Kiban Gijutsu Kenkyusho

    IPC分类号： C12N15/68 ,  C12N15/81 ,  C12N15/56 ,  C12P21/02 ,  C12N1/19

    CPC分类号： C12N9/2411 ,  C07K14/43 ,  C12N9/2408 ,  C12N15/815 ,  C12N15/905 ,  C12Y302/01001

    摘要： An object of the present invention is to provide a vector which can be integrated into a yeast chromosome in a high number of copies. Another object of the present invention is to provide a modified vector which can be integrated into the yeast chromosome in a high number of copies and of which expression units stably maintain on the chromosome. The vector according to the present invention comprises a marker gene for selecting transformants, a shortened promoter sequence which is operably linked to the marker gene and a sequence homologous to the chromosomal DNA of Candida utilis , and optionally a heterologous gene or a gene derived from C. utilis , wherein the vector is linearized by cleaving within said homologous DNA sequence or at both ends of the homologous DNA sequence with restriction enzymes, and wherein the heterologous gene or the gene derived from C. utilis can be integrated into the chromosomal DNA of C. utilis by homologous recombination.

    摘要翻译： 本发明的目的是提供一种能够以大量拷贝结合到酵母染色体中的载体。 本发明的另一个目的是提供一种修饰的载体，其能够以大量的拷贝整合到酵母染色体中，并且其表达单位稳定地保持在染色体上。 根据本发明的载体包含用于选择转化体的标记基因，与标记基因可操作地连接的缩短的启动子序列和与产朊假丝酵母的染色体DNA同源的序列，以及任选的异源基因或衍生自C的基因 其中载体通过在所述同源DNA序列内切割或用限制性内切酶在同源DNA序列的两端进行线性化，并且其中异源基因或源自产朊酵母的基因可以整合到C的染色体DNA中 通过同源重组产生。

    Vector
    116.
    发明公开
    Vector 失效
    VEKTOR。

    公开(公告)号：EP0502637A2

    公开(公告)日：1992-09-09

    申请号：EP92301465.8

    申请日：1992-02-21

    申请人： ZENECA LIMITED

    发明人： Barth, Peter Thomas

    IPC分类号： C12N15/63 ,  C12N15/68 ,  C07K15/00

    CPC分类号： C07K14/535 ,  C07K14/415 ,  C12N15/635 ,  C12N15/70 ,  C12N15/71

    摘要： The invention relates to vectors which include an inducible selection gene and a sequence which codes for a heterologous polypeptide. In a particular example the selection gene comprises the tet A and tet R genes. The vector may also include a sequence which is capable of conferring stability on the vector, such as the cer sequence, a transcription terminator, such as gene 32 from bacteriophage T4, a ribosome binding site, and a multi-cloning site. Hosts transformed with the vector, processes for preparing these hots, and processes for preparing polypeptides using these hosts.

    摘要翻译： 本发明涉及包含可诱导选择基因和编码异源多肽的序列的载体。 在特定实例中，选择基因包含tetA和tetR基因。 载体还可以包括能够赋予载体稳定性的序列，例如cer序列，转录终止子，例如噬菌体T4的基因32，核糖体结合位点和多克隆位点。 用载体转化的宿主，用于制备这些热点的方法，以及使用这些宿主制备多肽的方法。

    Stabilization of unstably inherited plasmids II.
    119.
    发明公开
    Stabilization of unstably inherited plasmids II. 失效
    Stabilisierung von unfesten geerbten Plasmiden。

    公开(公告)号：EP0206757A1

    公开(公告)日：1986-12-30

    申请号：EP86304700

    申请日：1986-06-18

    申请人： BENZON AS ALFRED

    发明人： MOLIN SOREN ,  GERDES KENN AXO ,  RASMUSSEN POUL BAAD ,  ANDERSSON POUL KIRKETERP

    IPC分类号： C12N15/00 ,  C12N15/09 ,  C12N15/67 ,  C12N15/68

    CPC分类号： C12N15/68 ,  C12N15/67 ,  Y10S435/874 ,  Y10S435/88

    摘要： The stable maintenance of a replicon in a population of growing cells is ensured by providing the replicon with a sequence which encodes a product capable of killing the cell harbouring the replicon or the progeny of the cell (or encodes a precursor for the product) and a sequence encoding an antagonist for the killing product (or a precursor for the antagonist). The antagonist is one which suppresses the killing product (or a precursor for the killing product) in cells harbouring the replicon, whereas the antagonist activity decays when the replicon is lost from the cell so that the antagonist (or its precursor) is no longer continuously expressed. This means that the killing product (or its precursor) present in the now replicon-free cell is no longer suppressed by the antagonist, resulting in cell death. Cells containing the thus stabilized replicon may be grown on a large scale without any significant loss of the replicon from the cell population even when no selection pressure is applied.

    摘要翻译： 通过向复制子提供编码能够杀死携带有细胞的复制子或后代的细胞的产物（或编码产物的前体）的序列，确保复制子在生长细胞群中的稳定维持，以及 编码杀死产物（或拮抗剂前体）的拮抗剂的序列。 拮抗剂是抑制在复制子的细胞中杀死产物（或杀死产物的前体）的拮抗剂，而当复制子从细胞中丢失时，拮抗剂活性衰减，使得拮抗剂（或其前体）不再连续 表达。 这意味着现在无复制子的细胞中存在的杀死产物（或其前体）不再被拮抗剂抑制，导致细胞死亡。 即使没有施加选择压力，含有如此稳定的复制子的细胞可以大规模生长，即使没有选择压力也不会从细胞群中显着损失复制子。

    VACCINES, A METHOD FOR MAKING VACCINES AND A METHOD FOR STIMULATING ANTIBODY PRODUCTION
    120.
    发明公开
    VACCINES, A METHOD FOR MAKING VACCINES AND A METHOD FOR STIMULATING ANTIBODY PRODUCTION 失效
    疫苗，制备疫苗的方法和刺激抗体生产的方法

    公开(公告)号：EP0060129A3

    公开(公告)日：1983-06-01

    申请号：EP82301181

    申请日：1982-03-08

    申请人： CETUS CORPORATION

    发明人： DALLAS, WALTER SOUTHWICK

    IPC分类号： C12N15/09 ,  A61K39/00 ,  A61K39/02 ,  A61K39/106 ,  A61K39/108 ,  C07K14/245 ,  C12N15/68 ,  C12R1/19

    CPC分类号： A61K39/0258 ,  A61K2039/523 ,  C07K14/245 ,  C12N15/68

    摘要： A vaccine is described for prevention of gastroenteric disease caused in a mammalian species by a pathogenic microorganism and which avoids, in its manufacture, the use of pathogens (which must be attenuated or killed) and the attendant risks, costs and complexity. The present vaccine comprises a nonpathogenic microorganism strain containing stable replicative plasmids, each having one or more genes non-indigenous to the plasmid. The non-indigenous genes are either genes for an adhesin necessay for adherence of the pathogenic microorganism in the mammalian species or are genes for toxoids of toxins causative of the disease. Both types of genes may also be included in the same plasmid. The invention includes the method of manufacture of such vaccines and their use in stimulating the production of antibodies.